Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Neuvasq Biotechnologies logo — Advancing neurological therapies to safeguard or rebuild CNS...

Neuvasq Biotechnologies

Advancing neurological therapies to safeguard or rebuild CNS barriers and ameliorate neurovascular function

Founded 2021 Belgium Belgium 13 employees Series A Total: $20.00M Biotechnology, Pharmaceutical

General Information

Company Name Neuvasq Biotechnologies
Founded Year 2021
Location Belgium Belgium +1
Employees 13
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Social

Get notified when Neuvasq Biotechnologies moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Neuvasq Biotechnologies

NeuVasQ, a Belgium-based biotechnology and pharmaceutical startup founded in 2021, is making strides in advancing neurological therapies. With the slogan "Advancing neurological therapies to safeguard or rebuild CNS barriers and ameliorate neurovascular function," Neuvasq Biotechnologies is focused on developing groundbreaking therapies for patients with severe neurological conditions. The company recently secured a notable €20.00M Series A investment on 24 June 2021 from Newton BioCapital. This funding will likely play a crucial role in driving NeuVasQ's innovative research and development efforts forward. Such substantial backing is a testament to the promise and potential NeuVasQ holds in addressing critical unmet needs in the neurological treatment landscape.

Taxonomy: Neurological therapies, CNS barriers, Neurovascular function, Biotechnologies, Discovery, Development, Pioneering therapies, Severe neurological conditions, Research company

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 1
Investor
24 Jun 2021

Neuvasq Biotechnologies Alternatives & Competitors

Neuvasq Biotechnologies vs
Aatalklinik Wünnenberg GmbH
Aatalklinik Wünnenberg GmbH Germany

Comprehensive health care solutions through diverse therapies, clinics, and medicinal services

9 employees
Health Care
Neuvasq Biotechnologies vs
NeuroVia
NeuroVia

Dedicated to halting the progression of severe neurological disorders and improving patient outcomes...

Series A
Biopharma, Biotechnology
Neuvasq Biotechnologies vs
Alcyone Therapeutics Inc.
Alcyone Therapeutics Inc. United States

Alcyone is pioneering next-generation intra-CSF (cerebrospinal fluid) CNS precision gene-based thera...

Series Unknown
37 employees
Biotechnology, Health and Wellness

FAQ About Neuvasq Biotechnologies

Advancing neurological therapies to safeguard or rebuild CNS barriers and ameliorate neurovascular function
Neuvasq Biotechnologies was founded in 2021.
Neuvasq Biotechnologies is headquartered in Belgium.
Neuvasq Biotechnologies operates in the following industries: Biotechnology, Pharmaceutical.
Neuvasq Biotechnologies has approximately 13 employees.
Neuvasq Biotechnologies has completed 1 funding round, raising a total of $20.00M. The latest funding stage is Series A.
Top alternatives and competitors to Neuvasq Biotechnologies include Aatalklinik Wünnenberg GmbH, NeuroVia, Alcyone Therapeutics Inc., Zhongze Therapeutics, VivaZome Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Neuvasq Biotechnologies and Aatalklinik Wünnenberg GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Neuvasq Biotechnologies and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy